AIM ImmunoTech Inc (AMEX: AIM) has experienced a decline in its stock price by -1.61 compared to its previous closing price of 0.13. However, the company has seen a gain of 1.16% in its stock price over the last five trading days. globenewswire.com reported 2025-02-28 that Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains
Is It Worth Investing in AIM ImmunoTech Inc (AMEX: AIM) Right Now?
The 36-month beta value for AIM is at 0.75. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AIM is 60.91M, and currently, shorts hold a 5.60% of that float. The average trading volume for AIM on March 06, 2025 was 1.06M shares.
AIM’s Market Performance
AIM stock saw a decrease of 1.16% in the past week, with a monthly decline of -28.16% and a quarterly a decrease of -40.38%. The volatility ratio for the week is 15.30%, and the volatility levels for the last 30 days are 15.31% for AIM ImmunoTech Inc (AIM). The simple moving average for the past 20 days is -4.97% for AIM’s stock, with a -53.08% simple moving average for the past 200 days.
AIM Trading at -27.15% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.13% of loss for the given period.
Volatility was left at 15.31%, however, over the last 30 days, the volatility rate increased by 15.30%, as shares sank -7.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.82% lower at present.
During the last 5 trading sessions, AIM rose by +3.36%, which changed the moving average for the period of 200-days by -66.10% in comparison to the 20-day moving average, which settled at $0.1363. In addition, AIM ImmunoTech Inc saw -34.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from Equels Thomas K, who purchase 50,000 shares at the price of $0.13 back on Mar 05 ’25. After this action, Equels Thomas K now owns 1,858,029 shares of AIM ImmunoTech Inc, valued at $6,730 using the latest closing price.
Equels Thomas K, the CEO & President of AIM ImmunoTech Inc, purchase 44,000 shares at $0.12 during a trade that took place back on Mar 04 ’25, which means that Equels Thomas K is holding 1,808,029 shares at $5,060 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -146.88 for the present operating margin
- 0.2 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -125.94. The total capital return value is set at -8.0. Equity return is now at value -187.58, with -115.46 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -6.08. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is -25.67.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 60.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, AIM ImmunoTech Inc (AIM) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
